Beam Therapeutics (BEAM) Short Interest Ratio & Short Volume

Short interest is the volume of Beam Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 13,450,000 shares of BEAM short. Learn More on Beam Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BEAM shares currently have a short interest ratio of 10.0. Learn More on Beam Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Beam Therapeutics: Citadel Advisors LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Beam Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 13,450,000 shares, a drop of 6.1% from the previous total of 14,320,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Beam Therapeutics: Intellia Therapeutics, Inc. (15.38%), Kymera Therapeutics, Inc. (14.83%), Ginkgo Bioworks Holdings, Inc. (20.21%), Vericel Co. (9.07%), Sana Biotechnology, Inc. (22.16%), Fusion Pharmaceuticals Inc. (6.13%), Denali Therapeutics Inc. (8.39%), Recursion Pharmaceuticals, Inc. (27.13%), Neumora Therapeutics, Inc. (10.10%), Twist Bioscience Co. (21.20%),

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

Short selling BEAM is an investing strategy that aims to generate trading profit from Beam Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Beam Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BEAM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BEAM, twice per month. The most recent reporting period available is March, 31 2024.